ESH AL 2024 | The future of frontline treatment in ALL: immunotherapy
Mark Litzow, MD, Mayo Clinic Rochester, Rochester, MN, discusses the future of frontline treatment for patients with acute lymphoblastic leukemia (ALL), with a prediction that immunotherapies will move into earlier lines. Following positive results from the ECOG-E1910 trial (NCT02003222) evidencing early treatment with blinatumomab, as well as trials showing the efficacy of inotuzumab ozogamicin, Dr Litzow anticipates a shift towards greater reliance on immunotherapy in frontline treatments, reducing dependence on chemotherapy. He also highlights the integration of CAR-T therapies into the frontline setting. This interview took place at the 4th European School of Hematology Acute Leukemia (ESH AL) congress in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Amgen: Research Funding, Consultancy; Astellas: Research Funding; Novartis: Research Funding; Syndax: Research Funding; Jazz: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Actinium: Research Funding; Pluristem: Research Funding; Biosight: Consultancy, Other: Data Monitoring Board; Abbvie: Research Funding; Beigene: Consultancy.
